<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Angelis Consulting Group | Ludvigsen | Activity</title>
	<link>https://angelisconsulting.com/members/saltgrey7/activity/</link>
	<atom:link href="https://angelisconsulting.com/members/saltgrey7/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Ludvigsen.</description>
	<lastBuildDate>Sun, 01 Nov 2026 14:36:02 -0600</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">39bb91b6a8a1509b7fe32a76264d8f25</guid>
				<title>Ludvigsen posted an update: Multiple Myeloma Lawsuits: What Patients Need to Know About [&#133;]</title>
				<link>https://angelisconsulting.com/activity/p/42217/</link>
				<pubDate>Sat, 15 Aug 2026 21:12:32 -0500</pubDate>

									<content:encoded><![CDATA[<p><strong>Multiple Myeloma Lawsuits: What Patients Need to Know About Legal Options, Compensation, and the Science Behind the Claims</strong> </p>
<p><em>Word count: ≈ 1,050</em> </p>
<p>Intro</p>
<p>Multiple myeloma (MM) is a malignant plasma‑cell condition that accounts for roughly 1% of all cancers and about 10% of hematologic malignancies in the United States. While advances in&hellip;<span class="activity-read-more" id="activity-read-more-42217"><a href="https://angelisconsulting.com/activity/p/42217/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6b84de5caed90aa319b544de9f6cb4f8</guid>
				<title>Ludvigsen posted an update: Understanding the Landscape: Multiple Myeloma Class Action [&#133;]</title>
				<link>https://angelisconsulting.com/activity/p/42141/</link>
				<pubDate>Sat, 15 Aug 2026 20:40:05 -0500</pubDate>

									<content:encoded><![CDATA[<p>Understanding the Landscape: Multiple Myeloma Class Action Lawsuits and What Patients Need to Know</p>
<p>Multiple myeloma, a complex cancer of plasma cells in the bone marrow, presents considerable obstacles for clients and their households. Beyond the medical journey, individuals diagnosed with this disease sometimes explore whether external&hellip;<span class="activity-read-more" id="activity-read-more-42141"><a href="https://angelisconsulting.com/activity/p/42141/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">74b8801ca0853f86e11790588498dc4b</guid>
				<title>Ludvigsen posted an update: Understanding the Landscape: Multiple Myeloma Lawsuits, [&#133;]</title>
				<link>https://angelisconsulting.com/activity/p/42081/</link>
				<pubDate>Sat, 15 Aug 2026 20:19:53 -0500</pubDate>

									<content:encoded><![CDATA[<p>Understanding the Landscape: Multiple Myeloma Lawsuits, Allegations, and What Patients Should Know</p>
<p>Multiple myeloma (MM), a cancer of plasma cells in the bone marrow, represents roughly 1.8% of all brand-new cancer cases in the United States each year, according to the American Cancer Society. While improvements in treatment have actually&hellip;<span class="activity-read-more" id="activity-read-more-42081"><a href="https://angelisconsulting.com/activity/p/42081/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">802b1e86ab7315e2883d37c3da5dad95</guid>
				<title>Ludvigsen became a registered member</title>
				<link>https://angelisconsulting.com/activity/p/42069/</link>
				<pubDate>Sat, 15 Aug 2026 20:17:44 -0500</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>